Trevia (Sitagliptin) is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control as:
– Monotherapy
– Dual Therapy
combination with metformin HCl or with a sulphonylurea or with a PPARγ agonist (i.e., thiazolidinediones) when the treatment with thesingle agent alone with diet and exercise does not provide adequate glycemic control.
-Triple Therapy
combination with metformin HCl and a sulphonylurea or with metformin HCl and a PPARγ (i.e., thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control. – Combination with Insulin.
